Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis.
Acute hepatitis C virus infection is associated with high rates of spontaneous clearance and variable rates of treatment-induced clearance. The benefit of early treatment versus awaiting spontaneous clearance is unknown, as is the optimal timing of treatment.We performed a MEDLINE and EMBASE search for the time period 1950 to October 2008. All English language abstracts using the search terms acute hepatitis C, hepatitis C and acute and hepatitis C and acute disease or acute infection were reviewed. Bibliographies were reviewed.Twenty-two studies including 1075 patients met the inclusion criteria. The sustained virologic response (SVR) rate for treated patients was 78%, significantly higher than 55.1% in untreated patients (OR = 3.08, 95% CI: 1.8-4.8 P value <0.0001). Mean time from diagnosis to spontaneous clearance was 9.7 weeks (SD 6.5). SVR rates varied inversely with time from acute HCV diagnosis. SVR rates for treatment within 12 weeks was 82.5% (95% CI: 75.6-89.3), significantly better than the clearance rates in untreated patients (P < 0.001). Response rates fell to 66.9% for treatment between 12 and 24 weeks, and decreased further to 62.5% for treatment beyond 24 weeks. Rates of viral clearance in treated patients with acute hepatitis C virus infection were significantly higher than that in untreated patients. Treatment rates were highest when treatment was initiated within 12 weeks of diagnosis. Based on these findings, we would advocate a 12 week period of observation for spontaneous clearance before treatment initiation. If no clearance has occurred by 12 weeks, treatment should be initiated.
Corey
K E
KE
Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA.
Mendez-Navarro
J
J
Gorospe
E C
EC
Zheng
H
H
Chung
R T
RT
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
D000998:Antiviral Agents
J Viral Hepat. 2007 Feb;14(2):116-21
17244251
Hepatology. 2002 Oct;36(4 Pt 1):993-1000
12297849
Gastroenterology. 2006 Mar;130(3):632-8
16530503
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S14-7
16265608
Hepatology. 2004 Jun;39(6):1721-31
15185314
Clin Gastroenterol Hepatol. 2006 Oct;4(10):1278-82
16931171
J Hepatol. 1994 Nov;21(5):831-6
7890900
Gastroenterology. 2003 Jul;125(1):80-8
12851873
N Engl J Med. 2001 Nov 15;345(20):1452-7
11794193
J Med Virol. 2001 Nov;65(3):505-9
11596085
Hepatology. 2000 Mar;31(3):777-82
10706572
Lancet. 1991 Oct 12;338(8772):914-5
1681268
Medicina (Kaunas). 2008;44(7):510-20
18695347
Hepatology. 2004 May;39(5):1213-9
15122749
Clin Infect Dis. 2007 Sep 1;45(5):583-8
17682992
Aliment Pharmacol Ther. 2004 Jul 1;20(1):15-22
15225166
Hepatology. 2003 Jan;37(1):60-4
12500189
N Engl J Med. 1999 Aug 19;341(8):556-62
10451460
J Infect Dis. 2007 Nov 15;196(10):1474-82
18008226
Ann Intern Med. 2000 Feb 15;132(4):296-305
10681285
J Hepatol. 2005 Mar;42(3):323-8
15791696
J Antimicrob Chemother. 2008 Nov;62(5):860-5
18776191
J Hepatol. 2005 Mar;42(3):329-33
15710214
Hepatology. 2006 May;43(5):923-31
16628640
Hepatology. 2006 Feb;43(2):250-6
16440367
J Hosp Infect. 2007 Sep;67(1):86-91
17719679
Ren Fail. 2007;29(6):731-6
17763169
Dig Liver Dis. 2003 Feb;35(2):104-13
12747629